Disease Progression and Pharmacodynamics in Parkinson Disease – Evidence for Functional Protection with Levodopa and Other Treatments

被引：0
作者：
Nicholas H. G. Holford
Phylinda L. S. Chan
John G. Nutt
Karl Kieburtz
Ira Shoulson
机构：
[1] University of Auckland,Department of Pharmacology & Clinical Pharmacology
[2] Oregon Health & Science University,Dept of Neurology
[3] Parkinson Study Group,Dept of Neurology
来源：
Journal of Pharmacokinetics and Pharmacodynamics | 2006年 / 33卷
关键词：
levodopa; deprenyl; bromocriptine; pergolide; pharmacodynamics; disease progression; Parkinson’s disease;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
We have modelled the Unified Parkinson’s Disease Rating Scale (UPDRS) scores collected in 800 subjects followed for 8 years. Newly diagnosed and previously untreated subjects were initially randomized to treatment with placebo, deprenyl, tocopherol or both and, when clinical disability required, received one or more dopaminergic agents (levodopa (carbidopa / levodopa), bromocriptine, or pergolide). Using models for disease progression and pharmacodynamic models for drug effects we have characterized the changes in UPDRS over time to determine the influence of the various drug treatments. We have confirmed and quantitated the relative symptomatic benefits of the dopaminergic agents and provide model-based evidence for slowing of disease progression.
引用
收藏
页码：281 / 311
页数：30
相关论文
共 100 条
[1]  
Fahn S.(1999)Parkinson disease, the effect of levodopa, and the ELLDOPA trial Earlier vs Later L-DOPA. Arch. Neurol. 56 529-535
[2]  
Schulzer M.(1992)The antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomatic Ann. Neurol. 32 795-798
[3]  
Mak E.(2003)Slower progression of Parkinson’s disease with ropinirole versus levodopa: The REAL-PET study Ann. Neurol. 54 93-101
[4]  
Calne D.B.(2002)Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression J. Am. Med. Assoc 287 1653-1661
[5]  
Whone A.L.(1992)A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer’s disease The Tacrine Collaborative Study Group N. Engl. J. Med. 327 1253-1259
[6]  
Watts R.L.(1993)Effects of tocopherol and deprenyl on the progression of disability in early Parkinson’s disease N. Engl. J. Med. 328 176-183
[7]  
Stoessl A.J.(2001)Drug treatment effects on disease progression Annu. Rev. Pharmacol. Toxicol. 41 625-659
[8]  
Davis M.(2000)Simulation of clinical trials Annu. Rev. Pharmacol. Toxicol. 40 209-234
[9]  
Reske S.(1989)Effect of deprenyl on the progression of disability in early Parkinson’s disease N. Engl. J. Med. 321 1364-1371
[10]  
Nahmias C.(1981)Understanding the dose-effect relationship: Clinical application of pharmacokinetic-pharmacodynamic models Clin. Pharmacokinet. 6 429-453
12345678910